Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 97

Similar articles for PubMed (Select 20688214)

1.

Viral endomyocardial infection is an independent predictor and potentially treatable risk factor for graft loss and coronary vasculopathy in pediatric cardiac transplant recipients.

Moulik M, Breinholt JP, Dreyer WJ, Kearney DL, Price JF, Clunie SK, Moffett BS, Kim JJ, Rossano JW, Jefferies JL, Bowles KR, O'Brian Smith E, Bowles NE, Denfield SW, Towbin JA.

J Am Coll Cardiol. 2010 Aug 10;56(7):582-92. doi: 10.1016/j.jacc.2010.02.060.

2.

Association of viral genome with graft loss in children after cardiac transplantation.

Shirali GS, Ni J, Chinnock RE, Johnston JK, Rosenthal GL, Bowles NE, Towbin JA.

N Engl J Med. 2001 May 17;344(20):1498-503.

3.

Association of parvovirus B19 genome in children with myocarditis and cardiac allograft rejection: diagnosis using the polymerase chain reaction.

Schowengerdt KO, Ni J, Denfield SW, Gajarski RJ, Bowles NE, Rosenthal G, Kearney DL, Price JK, Rogers BB, Schauer GM, Chinnock RE, Towbin JA.

Circulation. 1997 Nov 18;96(10):3549-54.

4.

Diagnosis, surveillance, and epidemiologic evaluation of viral infections in pediatric cardiac transplant recipients with the use of the polymerase chain reaction.

Schowengerdt KO, Ni J, Denfield SW, Gajarski RJ, Radovancevic B, Frazier HO, Demmler GJ, Kearney D, Bricker JT, Towbin JA.

J Heart Lung Transplant. 1996 Feb;15(2):111-23.

PMID:
8672514
5.

Positive pretransplantation cytomegalovirus serology is a risk factor for cardiac allograft vasculopathy in children.

Hussain T, Burch M, Fenton MJ, Whitmore PM, Rees P, Elliott M, Aurora P.

Circulation. 2007 Apr 3;115(13):1798-805. Epub 2007 Mar 12.

6.

Viral triggers of cardiac-allograft dysfunction.

Avery RK.

N Engl J Med. 2001 May 17;344(20):1545-7. No abstract available.

PMID:
11357160
7.

Socioeconomic position and graft failure in pediatric heart transplant recipients.

Singh TP, Gauvreau K, Bastardi HJ, Blume ED, Mayer JE.

Circ Heart Fail. 2009 May;2(3):160-5. doi: 10.1161/CIRCHEARTFAILURE.108.800755. Epub 2009 Apr 7.

8.

Risk factor analysis for the major hazards following heart transplantation--rejection, infection, and coronary occlusive disease.

Sharples LD, Caine N, Mullins P, Scott JP, Solis E, English TA, Large SR, Schofield PM, Wallwork J.

Transplantation. 1991 Aug;52(2):244-52.

PMID:
1871797
9.

Graft vasculopathy among recipients of heart transplantation during the first 12 years of life. The Pediatric Heart Transplant Group.

Bailey LL, Zuppan CW, Chinnock RE, Johnston JK, Razzouk AJ, Gundry SR.

Transplant Proc. 1995 Jun;27(3):1921-5. No abstract available.

PMID:
7792838
10.

Utility of post-transplant anti-HLA antibody measurements in pediatric cardiac transplant recipients.

Xydas S, Yang JK, Burke EM, Chen JM, Addonizio LJ, Mital SR, Itescu S, Hsu DT, Lamour JM.

J Heart Lung Transplant. 2005 Sep;24(9):1289-96.

PMID:
16143247
11.

Risk factors for primary graft failure after pediatric cardiac transplantation: importance of recipient and donor characteristics.

Huang J, Trinkaus K, Huddleston CB, Mendeloff EN, Spray TL, Canter CE.

J Heart Lung Transplant. 2004 Jun;23(6):716-22.

PMID:
15366432
12.

The impact and outcome of transplant coronary artery disease in a pediatric population: a 9-year multi-institutional study.

Pahl E, Naftel DC, Kuhn MA, Shaddy RE, Morrow WR, Canter CE, Kirklin J; Pediatric Heart Transplant Study.

J Heart Lung Transplant. 2005 Jun;24(6):645-51.

PMID:
15949722
13.

Complications of endomyocardial biopsy in children.

Pophal SG, Sigfusson G, Booth KL, Bacanu SA, Webber SA, Ettedgui JA, Neches WH, Park SC.

J Am Coll Cardiol. 1999 Dec;34(7):2105-10.

14.

Surveillance for transplant coronary artery disease in infant, child and adolescent heart transplant recipients: an intravascular ultrasound study.

Nicolas RT, Kort HW, Balzer DT, Trinkaus K, Dent CL, Hirsch R, Canter CE.

J Heart Lung Transplant. 2006 Aug;25(8):921-7. Epub 2006 Jul 11.

PMID:
16890112
15.

Effects of methotrexate on acute rejection and cardiac allograft vasculopathy in heart transplant recipients.

Costanzo MR, Koch DM, Fisher SG, Heroux AL, Kao WG, Johnson MR.

J Heart Lung Transplant. 1997 Feb;16(2):169-78.

PMID:
9059928
16.

Pravastatin therapy is associated with reduction in coronary allograft vasculopathy in pediatric heart transplantation.

Mahle WT, Vincent RN, Berg AM, Kanter KR.

J Heart Lung Transplant. 2005 Jan;24(1):63-6.

PMID:
15653381
17.

Long-term results of triple-drug-based immunosuppression in nonneonatal pediatric heart transplant recipients.

Gajarski RJ, Smith EO, Denfield SW, Rosenblatt HM, Kearney D, Frazier OH, Radovancevic B, Price JK, Kertesz NJ, Towbin JA.

Transplantation. 1998 Jun 15;65(11):1470-6.

PMID:
9645805
18.

Transforming growth factor beta in relation to cardiac allograft vasculopathy after heart transplantation.

Aziz T, Hasleton P, Hann AW, Yonan N, Deiraniya A, Hutchinson IV.

J Thorac Cardiovasc Surg. 2000 Apr;119(4 Pt 1):700-8.

PMID:
10733758
19.

Early results after pediatric cardiac transplantation with triple immunosuppression therapy.

Canter CE, Saffitz JE, Moorhead S, Gutierrez FR, Bolman RM, Spray TL.

Am J Cardiol. 1993 Apr 15;71(11):971-5.

PMID:
8465791
20.

Influence of tumor necrosis factor-alpha gene-308 polymorphism on the development of coronary vasculopathy after cardiac transplantation.

Densem CG, Hutchinson IV, Yonan N, Brooks NH.

J Heart Lung Transplant. 2001 Dec;20(12):1265-73.

PMID:
11744409
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk